Consensus Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
93 ^USD	+2.50%		+7.08%	+0.82%

04-25	Transcript : Blueprint Medicines Corporation - Special Call
03-22	Blueprint Medicines Insider Sold Shares Worth $2,188,265, According to a Recent SEC Filing	MT

Evolution of the average Target Price on Blueprint Medicines Corporation

Price target over the last 5 years

History of analyst recommendation changes

e1e7acb73de.agMa8EnGRqb-KvPmtM-P9yQS32L57x5KUoKol6SQn7E.LlVsvS3yFfeGdYWL66f9gGMi6RLLoF8eG8vR-8293OdYdCKDeusP3LwHmA~d19bef9483d4f8157f67e265068c3600

Analyst Recommendations on Blueprint Medicines Corporation

Wedbush Adjusts Blueprint Medicines' PT to $110 From $97, Keeps Outperform Rating	02-15	MT
Barclays Increases Price Target on Blueprint Medicines to $70 From $58, Maintains Equalweight Rating	02-13	MT
Oppenheimer Raises Blueprint Medicines Price Target to $90 From $85, Maintains Outperform Rating	01-31	MT
Stifel Adjusts Blueprint Medicines' Price Target to $97 From $95, Keeps Buy Rating	01-09	MT
Wedbush Lowers Blueprint Medicines' PT to $97 From $100 After Discussion of Strategic Priorities for 2024, Pipeline Update; Keeps Outperform Rating	01-08	MT
Raymond James Adjusts Blueprint Medicines' Price Target to $100 From $85, Keeps Strong Buy Rating	12-22	MT
Wells Fargo Raises Blueprint Medicines Price Target to $115 From $86, Maintains Overweight Rating	12-19	MT
Wedbush Raises Blueprint Medicines Price Target to $100 From $80, Maintains Outperform Rating	12-11	MT
North American Morning Briefing : Rate Decisions, -2-	23-10-30	DJ
Morgan Stanley Adjusts Price Target on Blueprint Medicines to $63 From $59, Maintains Equalweight Rating	23-10-27	MT
Barclays Raises Price Target on Blueprint Medicines to $58 From $46, Maintains Equalweight Rating	23-10-27	MT
Needham Raises Blueprint Medicines Price Target to $74 From $66, Maintains Buy Rating	23-10-27	MT
Oppenheimer Upgrades Blueprint Medicines to Outperform From Perform, $85 Price Target	23-10-27	MT
Wedbush Raises Blueprint Medicines' Price Target to $80 From $75 After Higher-Than-Expected Q3 Financial Results, Keeps Outperform Rating	23-10-26	MT
Needham Adjusts Price Target on Blueprint Medicines to $66 From $65, Maintains Buy Rating	23-08-21	MT
Goldman Sachs Adjusts Price Target on Blueprint Medicines to $83 From $93, Maintains Buy Rating	23-08-03	MT
Morgan Stanley Adjusts Price Target on Blueprint Medicines to $59 From $55, Maintains Equal-Weight Rating	23-08-03	MT
Wells Fargo Upgrades Blueprint Medicines to Overweight From Equalweight, Adjusts Price Target to $82 From $55	23-07-31	MT
Wells Fargo Raises Price Target on Blueprint Medicines to $55 From $48, Maintains Equal-Weight Rating	23-06-14	MT
SVB Securities Downgrades Blueprint Medicines to Underperform From Market Perform, Cuts Price Target to $43 From $48	23-06-05	MT
Guggenheim Raises Price Target on Blueprint Medicines to $82 From $78, Maintains Buy Rating	23-05-23	MT
SVB Securities Adjusts Price Target on Blueprint Medicines to $48 From $45, Maintains Market Perform Rating	23-05-23	MT
Wells Fargo Adjusts Price Target on Blueprint Medicines to $48 From $47, Keeps Equalweight Rating	23-05-23	MT
HC Wainwright Adjusts Blueprint Medicines' Price Target to $85 From $75, Keeps Buy Rating	23-05-23	MT
Needham Adjusts Blueprint Medicines' Price Target to $67 From $65, Keeps Buy Rating	23-05-23	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

93 USD

Average target price

97.47 USD

Spread / Average Target

+4.81%

High Price Target

125 USD

Spread / Highest target

+34.41%

Low Price Target

50 USD

Spread / Lowest Target

-46.24%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Blueprint Medicines Corporation

Wedbush
Barclays
Oppenheimer
Stifel Nicolaus
Raymond James
Wells Fargo Securities
Morgan Stanley
Needham & Co.
Goldman Sachs
SVB Securities LLC
Guggenheim
HC Wainwright
Berenberg Bank
Jefferies & Co.
Citigroup
Piper Sandler
Baird
SVB Leerink
Credit Suisse

Ratings for Blueprint Medicines Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar